Duloxetine HCl lipid nanoparticles: Preparation, characterization, and dosage form design

AAPS PharmSciTech

Volumn 13, Issue 1, 2012, Pages 125-133

  Patel, Ketan ^a   Padhye, Sameer ^a   Nagarsenker, Mangal ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

Acid labile; Adsorption; Duloxetine HCl; Lymphatic absorption; Solid lipid nanoparticles

Indexed keywords

DULOXETINE; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG ADSORPTION; DRUG CONFORMATION; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG METABOLISM; DRUG RELEASE; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; X RAY DIFFRACTION; ZETA POTENTIAL;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DOSAGE FORMS; DRUG DESIGN; LIPIDS; MALE; MICE; NANOPARTICLES; PARTICLE SIZE; THIOPHENES; X-RAY DIFFRACTION;

EID: 84861100671     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-011-9727-6     Document Type: Article

References (22)

1. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25:871-80. (Pubitemid 34031892)
2. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol. 2000;40:161-7.
3. Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001;24:511-21. (Pubitemid 32244312)
4. Sinha VR, Kumria R, Bhinge JR. Stress degradation studies on duloxetine hydrochloride and development of an RP-HPLC method for its determination in capsule formulation. J Chromatogr Sci. 2009;47:589-93.
5. Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev. 2007;59:667-76. (Pubitemid 47285409)
6. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-77. (Pubitemid 30326695)
7. Kumar VV, Chandrasekar D, Ramakrishna S, Kishan V, Rao YM, Diwan PV. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm. 2007;335:167-75. (Pubitemid 46482862)
8. Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release. 2006;114:53-9. (Pubitemid 44144503)
9. Muller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm. 2006;317:82-9. (Pubitemid 43866342)
10. Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech. 2007;8:24.
11. Bunjes H, Westesen K, Koch MHJ. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm. 1996;129:159-73. (Pubitemid 26098737)
12. Zimmermann E, Muller RH, Mader K. Influence of different parameters on reconstitution of lyophilized SLN. Int J Pharm. 2000;196:211-3.
13. Freitas C, Mullera RH. Spray-drying of solid lipid nanoparticles (SLN TM). Eur J Pharm Biopharm. 1998;46:145-51. (Pubitemid 28414472)
14. Cavalli R, Gasco MR, Barresi AA, Rovero G. Evaporative drying of aqueous dispersions of solid lipid nanoparticles. Drug Dev Ind Pharm. 2001;27:919-24. (Pubitemid 33101451)
15. Chakraborty S, Shukla D, Vuddanda PR, Mishra B, Singh S. Utilization of adsorption technique in the development of oral delivery system of lipid based nanoparticles. Colloids Surf B Biointerfaces. 2010;81:563-9.
16. Dixit RP, Nagarsenker MS. Dry adsorbed emulsion of simvastatin: optimization and in vivo advantage. Pharm Dev Technol. 2007;12:495-504. (Pubitemid 350041533)
17. Dixit RP, Nagarsenker MS. Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation. Eur J Pharm Sci. 2008;35:183-92.
18. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 2004;95:627-38. (Pubitemid 38344153)
19. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release. 1999;59:299-307. (Pubitemid 29238174)
20. Ciulla L, Menezes HS, Bueno BB, Schuh A, Alves RJ, Abegg MP. Antidepressant behavioral effects of duloxetine and fluoxetine in the rat forced swimming test. Acta Cir Bras. 2007;22:351-4. (Pubitemid 47612600)
21. Li JT, Caldwell KD, Rapoport N. Surface properties of pluronic-coated polymeric colloids. Langmuir. 1994;10:4475-82.
22. Han F, Li S, Yin R, Liu H, Xu L. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: nanostructured lipid carriers. Colloids Surf A Physicochem Eng Asp. 2008;315:210-6. (Pubitemid 350298857)